+1-518-618-1030 866 - 552 - 3453 USA-Canada Toll Free
Published Date: 2016-04-01Number of Pages: 91

Opioid Induced Constipation Treatment Market: (Mu-opioid Receptor Antagonist, Chloride Channel Activator, and Others; Solid, Semi-solid, and Liquid): Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2015 - 2023

Global Opioid Induced Constipation Treatment Market: Snapshot

There are multiple drugs in the pipeline for opioid induced constipation treatment. Upon approval, these drugs will face little competition in this market which is largely untapped. There have not been many stable choices in the pharmaceutical industry for opioid induced constipation treatment over the recent past, but the continuous approval rate of highly targeted drugs is expected to provide a strong push to this market’s growth rate. This includes the PAMORA drugs that help treat OIC without intervening in the opioid’s action on the patient.

The number of patients suffering from opioid induced constipation is increasing across the globe. Close to 100 mn U.S. patients in 2013 were suffering from OIC, according to the American Academy of Pain Medicine. They added that this number is expected to increase as the number of people consuming opioid drugs increases. With a growing awareness of the commercial availability of a large variety of opioid drugs, people have resorted to using them for longer terms to treat chronic pains. This growing number of OIC patients – especially in North America – is expected to further drive the demand for opioid induced constipation treatment.

There is, however, the competition that opioid induced constipation treatment providers face from standard laxatives. Most healthcare organizations still consider standard laxatives as the first line of treatment for OIC. Additionally, the long term adverse effects of opioid induced constipation treatments have not completely been documented.

All in all, the global market for opioid induced constipation treatment is expected to be valued at US$731.2 mn by the end of 2016. Owing to a whopping CAGR of 31.2% from 2015 to 2023, this revenue is expected to reach US$4.8 bn by 2023.

North America Consumption of OIC Treatment Trumps Other Regions

North America has always taken up a large chunk of the global consumption of opioid induced constipation treatment drugs. By the end of 2023, North America alone is expected to generate US$4.05 bn of the global revenue from opioid induced constipation treatments. This region also leads in terms of growth rate of demand, owing to the large percentage of population that consumes opioid drugs and suffers from OIC. This comes from a high number of patients that are suffering from chronic diseases and are resorting to opioids.

Additionally, the penetration of opioid induced constipation treatments is very low in other regions as compared to North America. This could be the reason for the high disparity of consumption rates between regions. At the moment, North America dominates in terms of opioid consumption. According to the ASIPP, the U.S. alone consumes close to 80% of the global supply of opioids. 

Mu-opioid Receptor Antagonists to Overtake Chloride Channel Activators by 2023

Till the end of 2016, chloride channel activators are expected to be the more popular drug class of opioid induced constipation treatments. This trend will continue for the coming years, but in time it is predicted that mu-opioid receptor antagonists will take the leading role among drug classes. A key reason for the popularity of chloride channel activators is the high level of sales of Amitiza ever since it was approved in 2013 and used specifically for opioid induced constipation treatment.

Over time, the growing number of mu-opioid receptor antagonists being approved and their greater efficacy over other drug classes is expected to push it to the top of the charts in terms of revenue generation before 2023. This drug class will also benefit from the increasing number of prescriptions being filed for opioid induced constipation treatments due to developments that reduce their side effects.

The leading providers of opioid induced constipation treatment include AstraZeneca, Takeda Pharmaceutical Company Limited, Abbott Laboratories, Valeant, Bayer, C.B. Fleet Company, Inc., Boehringer Ingelheim, Daewoong Co. Ltd., and Cosmo Pharmaceuticals.


1. Preface
     1.1. Report Description
     1.2. Research Methodology
     1.3. Market Segmentation

2. Executive Summary
     2.1. Market Snapshot

3. Opioid Induced Constipation Treatment Market - Industry Analysis
     3.1. Introduction
     3.2. Event Impact Analysis 
     3.3. Pain 
     3.4. Market Dynamics
            3.4.1. Drivers
            3.4.2. Restraints
            3.4.3. Opportunities
     3.5. Regulatory Scenario
     3.6. Competitive Landscape
3.6.1. Market Share Analysis of Key Players, 2014 (Value %)
     3.7. Market Attractiveness Analysis of Global Opioid Induced Constipation Treatment Market, by Geography, 2014 

4. Market Segmentation - By Dosage Form of the Drug 
     4.1. Introduction 
     4.2. Global Solid Dosage Form Market Revenue, 2013–2023 (US$ Mn) and Analysis
     4.3. Global Semi-solid Dosage Form Market Revenue, 2013–2023 (US$ Mn) and Analysis
     4.4. Global Liquid Dosage Form Market Revenue, 2013–2023 (US$ Mn) and Analysis

5. Market Segmentation - By Drug Class
     5.1. Introduction 
     5.2. Global Mu Opioid Receptor Antagonist Market Revenue, 2013–2023 (US$ Mn) and Analysis
     5.3. Global Chloride Channel Activator Market Revenue, 2013–2023 (US$ Mn) and Analysis
     5.4. Global Others Market Revenue, 2013–2023 (US$ Mn) and Analysis

6. Pipeline Analysis
     6.1. Overview 
     6.2. Late Stage (Phase III) 
            6.2.1. Naldemedine
            6.2.2. Others
     6.3. Early Stage (Phase I and II) (Qualitative Analysis - Tabular representation)

7. Market Segmentation - By Geography
     7.1. Introduction
     7.2. Global Opioid Induced Constipation Treatment Market Revenue, by Region, 2013–2023 (US$ Mn)
     7.3. North America Opioid Induced Constipation Treatment Market Revenue, by Country, 2013–2023 (US$ Mn)
            7.3.1. U.S. Opioid Induced Constipation Treatment Market Revenue, 2013–2023, (US$ Mn)
            7.3.2. Canada Opioid Induced Constipation Treatment Market Revenue, 2013–2023, (US$ Mn)
     7.4. Europe Opioid Induced Constipation Treatment Market – Revenue, by Country, 2013–2023 (US$ Mn)
            7.4.1. U.K. Opioid Induced Constipation Treatment Market Revenue, 2013–2023, (US$ Mn)
            7.4.2. Germany Opioid Induced Constipation Treatment Market Revenue, 2013–2023, (US$ Mn)
            7.4.3. France Opioid Induced Constipation Treatment Market Revenue, 2013–2023, (US$ Mn)
            7.4.4. Rest of Europe Opioid Induced Constipation Treatment Market Revenue, 2013–2023, (US$ Mn)
     7.5. Asia Pacific Opioid Induced Constipation Treatment Market Revenue, by Country, 2013–2023 (US$ Mn)
            7.5.1. Australia Opioid Induced Constipation Treatment Market Revenue, 2013–2023, (US$ Mn)
            7.5.2. Japan Opioid Induced Constipation Treatment Market Revenue, 2013–2023, (US$ Mn)
            7.5.3. South Korea Opioid Induced Constipation Treatment Market Revenue, 2013–2023, (US$ Mn)
            7.5.4. Rest of APAC Opioid Induced Constipation Treatment Market Revenue, 2013–2023, (US$ Mn)
     7.6. Latin America Opioid Induced Constipation Treatment Market Revenue, by Country, 2013–2023 (US$ Mn)
            7.6.1. Brazil Opioid Induced Constipation Treatment Market Revenue, 2013–2023, (US$ Mn)
            7.6.2. Rest of Latin America Opioid Induced Constipation Treatment Market Revenue, 2013–2023, (US$ Mn)
     7.7. Rest of the World Opioid Induced Constipation Treatment Market Revenue, by Country, 2013–2023 (US$ Mn)

8. Recommendations

9. Company Profiles
     9.1. Abbott Laboratories, Inc.
     9.2. AstraZeneca plc
     9.3. Bayer AG
     9.4. Boehringer Ingelheim GmbH
     9.5. C.B. Fleet Company, Inc.
     9.6. COSMO Pharmaceuticals
     9.7. Daewoong Pharmaceutical Co. Ltd. 
     9.8. Takeda Pharmaceutical Co., Ltd.
     9.9. Valeant Pharmaceuticals International, Inc. 

This report on the opioid induced constipation treatment market studies the current and future scenario of the global market. Large number of chronic pain sufferers is responsible for rising opioid consumption. Severe chronic constipation is a major side effect of consumption of opioid and shows resistance to traditional laxatives. Hence, novel targeted therapy has been prescribed to treat opioid induced constipation. Rising number of OIC sufferers, launch of targeted medicines, and growing awareness about the therapy are the major drivers of the market. 

The opioid induced constipation treatment market report comprises an elaborate executive summary, which includes a market snapshot that provides information about various segments of the market. It also provides information and data analysis of the global market with respect to the segments based on the dosage form of the drug, type of drug class, and their geographical analysis. A detailed qualitative analysis of drivers and restraints of the market and opportunities has been provided in the market overview section. In addition, the section comprises regulatory framework for major countries and event impact analysis. This section of the report also provides market attractiveness analysis, by geography and market share analysis by key players, thus presenting a thorough analysis of the overall competitive scenario in the global opioid induced constipation treatment market. 

Based on dosage form of the drug, the market has been segmented into three major forms: solid, semi-solid, and liquid. The market segments have been analyzed based on available approved drugs for treatment and their dosage forms, cost-effectiveness, and preference for dosage form by physicians and patients. The market size and forecast for each of these segments have been provided for the period from 2013 to 2023, along with their respective CAGRs for the forecast period from 2015 to 2023, considering 2014 as the base year. 

Based on drug class, the opioid induced constipation treatment market has been segmented into three major categories based on their mechanism of action: mu opioid receptor antagonist (Movantik and Relistor), chloride channel activator (Amitiza), and others (Resolor and traditional medicines). The market segments have been extensively analyzed based on efficacy, cost, revenue, number of launched drugs, and geographical coverage. The market size and forecast in terms of US$ Mn for each segment have been provided for the period from 2013 to 2023. The report also provides the compound annual growth rate (CAGR %) for each market segment for the forecast period from 2015 to 2023, considering 2014 as the base year. 

Pipeline analysis has also been provided in the report. The market has been estimated for drugs that are in phase III (late stage) clinical trials. Presently, Naldemedine is an under NDA review. A tabular representation has been included for phase II and phase I drugs. 

Geographically, the global opioid induced constipation treatment market has been categorized into five major regions and the key countries in the respective region: North America (U.S., Canada), Europe (U.K., Germany, France, and Rest of Europe), Asia Pacific (Australia, Japan, South Korea, and Rest of Asia Pacific), Latin America (Brazil and Rest of Latin America) and Rest of the World. The market size and forecast for each of these regions and the mentioned countries has been provided for the period from 2013 to 2023, along with their respective CAGRs for the forecast period from 2015 to 2023, considering 2014 as the base year. The research study also covers the competitive scenario in these regions. 

The report also profiles major players in the global opioid induced constipation treatment market based on various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments. Major players profiled in this report include AstraZeneca plc, Takeda Pharmaceutical Company Limited, Abbott Laboratories, Valeant Pharmaceuticals International, Inc., Bayer AG, C.B. Fleet Company, Inc., Boehringer Ingelheim GmbH, Daewoong Co. Ltd., and Cosmo Pharmaceuticals. 

The global opioid induced constipation treatment market has been segmented as follows:

  • Global Opioid Induced Constipation Treatment Market Revenue, by Dosage form of Drugs, 2013–2023 (US$ Mn)
    • Solid
    • Semisolid
    • Liquid
  • Global Opioid Induced Constipation Treatment Market Revenue, by Drug Class, 2013–2023 (US$ Mn)
    • mu-opioid receptor antagonist
    • Chloride channel activator
    • Others
  • Global Opioid Induced Constipation Treatment Market Revenue, by Pipeline, 2013–2023 (US$ Mn)
    • Late Stage (phase III) candidates (forecast from the year of approval till 2023) (US$ Mn)
      • Naldemedine
      • Others
    • Early Stage (phase II and phase I) candidates (tabular representation)
      • Axelopran
      • Others
  • Global Opioid Induced Constipation Treatment Market Revenue, By Geography, 2013–2023 (US$ Mn)
    • Overview
    • North America
      • U.S.
      • Canada
    • Europe
      • U.K.
      • Germany
      • France
      • Rest of Europe
    • Asia Pacific
      • Australia
      • Japan
      • South Korea
      • Rest of Asia Pacific
    • Latin America
      • Brazil
      • Rest of Latin America
    • Rest of the World


 
 
Back To Top